Flow Cytometry in Oncology and Immunology Market Analysis and Forecast, 2022-2032

1
All rights reserved at BIS Research Inc.
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
Focus on Offering, Technology, End User,
Type, Application, and Country
Analysis and Forecast: 2022-2032
November 2022
Flow Cytometry
in Oncology and
Immunology
Market -
A Global Market
and Regional
Table of Content

2
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
BIS Research is a leading market intelligence and technology research company. BIS Research publishes in-
depth market intelligence reports focusing on the market estimations, technology analysis, emerging high-
growth applications, deeply segmented granular country-level market data and other important market
parameters useful in the strategic decision making for senior management. BIS Research provides multi-client
reports, company profiles, databases, and custom research services.
Copyright © 2022 BIS Research Inc.
All Rights Reserved. This document contains highly confidential information and is the sole property of BIS
Research. Disclosing, copying, circulating, quoting or otherwise reproducing any or all contents of this
document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people
or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third
party.

3
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
Table of Content
Executive Summary..........................................................................30
Scope of the Study ...........................................................................37
Research Methodology.....................................................................40
1. Markets .....................................................................................46
1.1 Global Market Outlook ....................................................................................47
1.1.1 Product Definition .......................................................................................47
1.1.2 Inclusion and Exclusion Criteria................................................................47
1.2 Market Overview ..............................................................................................48
1.2.1 Application of Flow Cytometry in Oncology .............................................48
1.2.1.1 Solid Tumor ....................................................................................................... 48
1.2.1.2 Hematological Malignancies.............................................................................. 48
1.2.2 Addressable Market Size and Growth Potential ($Million), 2021-2032
......................................................................................................................49
1.3 Industry Participants Landscape ...................................................................50
2. Industry Insights ........................................................................51
2.1 Regulatory Framework....................................................................................51
2.1.1 Regulatory Framework in the U.S. .............................................................51
2.1.1.1 Recommendations for Diagnostic Approval....................................................... 51
2.1.2 Regulatory Framework in Europe ..............................................................52
2.1.2.1 Recommendations for Diagnostic Approval....................................................... 52
2.1.3 Regulatory Framework in Asia-Pacific ......................................................53
2.1.3.1 China ................................................................................................................. 53
2.1.3.1.1 Recommendations for Diagnostic Approval............................................................. 53
2.1.3.2 Japan................................................................................................................. 53
2.1.3.2.1 Recommendations for Diagnostic Approval............................................................. 54
2.2 Reimbursement Scenario................................................................................54
2.2.1 North America..............................................................................................54
2.2.2 Europe..........................................................................................................56
2.2.3 Asia-Pacific..................................................................................................56

4
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
2.3 Product Mapping Analysis..............................................................................58
2.3.1 Global Flow Cytometry in Oncology and Immunology Market,
Product Mapping Analysis (by Offering)...................................................58
2.3.2 Global Flow Cytometry in Oncology and Immunology Market,
Product Mapping Analysis, (by Product) ..................................................59
2.3.3 Price Sensitivity Analysis...........................................................................59
2.4 Impact of COVID-19 on Global Flow Cytometry in Oncology and
Immunology Market.........................................................................................60
2.4.1 Impact of COVID-19 on Flow Cytometry Research...................................60
2.4.2 Pre-COVID-19 Phase ...................................................................................60
2.4.3 During-COVID-19 Phase..............................................................................61
2.4.4 Post-COVID-19 Phase .................................................................................62
2.5 Business Dynamics.........................................................................................63
2.5.1 Impact Analysis ...........................................................................................63
2.5.2 Business Drivers .........................................................................................64
2.5.2.1 Increasing Burden of Cancer is One of the Major Propelling Factors for the
Innovation of Novel Technologies in Flow Cytometry........................................ 64
2.5.2.2 Expansion of Applications in Flow Cytometry for Research Activities
Propels its Demand in the Market...................................................................... 65
2.5.2.3 Innovation in Flow Cytometry Leading to Use of Next-Generation Flow
Cytometers ........................................................................................................ 67
2.5.2.4 Increasing Use of Flow Cytometry in Identification and Diagnosis of
Immune-Deficiency Diseases ............................................................................ 67
2.5.3 Business Restraints....................................................................................68
2.5.3.1 High Cost of the Products of the Flow Cytometry Equipment Restraining
the Adoption of the Devices in Emerging Economies........................................ 68
2.5.3.2 False Negative and Positive Antibody Responses Can Hinder the Adoption
of Flow Cytometry.............................................................................................. 69
2.5.4 Business Opportunities..............................................................................70
2.5.4.1 Flow Cytometry as a Pivoting Technology in Solid Tumors in the Next 5-10
years.................................................................................................................. 70

5
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
2.5.4.2 Leveraging Public-Private Initiatives to Advance R&D in the Field of
Immunology and Oncology Research................................................................ 70
3. Global Flow Cytometry in Oncology and Immunology Market
(by Technology).........................................................................72
3.1 Opportunity Assessment ................................................................................73
3.2 Cell-Based Flow Cytometry ............................................................................74
3.3 Bead-Based Flow Cytometry ..........................................................................75
(by Offering) ..............................................................................76
4.2 Products ...........................................................................................................78
4.2.1 Instruments..................................................................................................79
4.2.2 Reagents and Consumables ......................................................................80
4.2.3 Software .......................................................................................................81
4.3 Services............................................................................................................82
(by Application) .........................................................................84
5.2 Translational Research ...................................................................................86
5.3 Clinical Research.............................................................................................87
5.3.1 Screening and Diagnostics ........................................................................88
5.3.2 Monitoring and Treatment ..........................................................................89
(by Type) ...................................................................................91
6.2 Immunology .....................................................................................................93
6.3 Oncology ..........................................................................................................95
6.3.1 Hematological Malignancies ......................................................................97
6.3.1.1 Hematological Malignancies (by Type).............................................................. 97
6.3.1.1.1 Lymphoma ............................................................................................................... 98
6.3.1.1.2 Leukemia................................................................................................................ 100

6
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
6.3.1.1.3 Myeloma................................................................................................................. 101
6.3.1.1.4 Other Hematological Malignancies ........................................................................ 102
6.3.1.2 Hematological Malignancies (by Technology) ................................................. 103
6.3.2 Solid Tumor ...............................................................................................104
6.3.2.1 Solid Tumor (by Type) ..................................................................................... 104
6.3.2.1.1 Breast Cancer ........................................................................................................ 105
6.3.2.1.2 Prostate Cancer ..................................................................................................... 107
6.3.2.1.3 Colorectal Cancer .................................................................................................. 108
6.3.2.1.4 Lung Cancer........................................................................................................... 109
6.3.2.1.5 Liver Cancer........................................................................................................... 110
6.3.2.1.6 Ovarian Cancer...................................................................................................... 111
6.3.2.1.7 Other Solid Tumors................................................................................................ 112
6.3.2.2 Solid Tumor (by Technology)........................................................................... 113
(by End User)...........................................................................114
7.1 Opportunity Assessment ..............................................................................115
7.2 Hospitals, Diagnostic Laboratories, and Reference Laboratories ............116
7.3 Pharmaceutical and Biotechnology Companies.........................................118
7.4 Academic Research Institutes......................................................................119
7.5 Contract Research Organizations ................................................................120
7.6 Others .............................................................................................................122
8. Region .....................................................................................123
8.1 North America Flow Cytometry in Oncology and Immunology Market.....125
8.1.1 Key Findings and Opportunity Assessment ...........................................125
8.1.2 Market Dynamics.......................................................................................126
8.1.2.1 Impact Analysis ............................................................................................. 126
8.1.3 Market Sizing and Forecast ......................................................................127
8.1.4 North America Flow Cytometry in Oncology and Immunology
Market (by Country)...................................................................................127
8.1.4.1 U.S................................................................................................................... 128

7
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
8.1.4.1.1 Market Dynamics ................................................................................................... 128
8.1.4.1.2 Cancer Incidence (by Type of Cancer) .................................................................. 129
8.1.4.1.3 Market Size and Forecast...................................................................................... 130
8.1.4.1.3.1 U.S. Flow Cytometry in Oncology and Immunology Market (by
Application)............................................................................................................ 130
8.1.4.1.3.2 U.S. Flow Cytometry in Oncology and Immunology Market (by Type of
Cancer).................................................................................................................. 131
8.1.4.2 Canada ............................................................................................................ 131
8.1.4.2.1 Market Dynamics ................................................................................................... 131
8.1.4.2.3.1 Canada Flow Cytometry in Oncology and Immunology Market (by
Application)............................................................................................................ 134
8.1.4.2.3.2 Canada Flow Cytometry in Oncology and Immunology Market (by Type
of Cancer).............................................................................................................. 134
8.2 Europe Flow Cytometry in Oncology and Immunology Market.................135
8.2.2 Market Dynamics.......................................................................................136
8.2.2.1 Impact Analysis ............................................................................................. 136
8.2.4 Europe Flow Cytometry in Oncology and Immunology Market (by
Country) .....................................................................................................137
8.2.4.1 Germany.......................................................................................................... 138
8.2.4.1.1 Market Dynamics ................................................................................................... 138
8.2.4.1.3.1 Germany Flow Cytometry in Oncology and Immunology Market (by
Application)............................................................................................................ 140
8.2.4.1.3.2 Germany Flow Cytometry in Oncology and Immunology Market (by Type
of Cancer).............................................................................................................. 140
8.2.4.2 France.............................................................................................................. 141

8
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
8.2.4.2.1 Market Dynamics ................................................................................................... 141
8.2.4.2.3.1 France Flow Cytometry in Oncology and Immunology Market (by
Application)............................................................................................................ 143
8.2.4.2.3.2 France Flow Cytometry in Oncology and Immunology Market (by Type of
Cancer).................................................................................................................. 144
8.2.4.3 U.K................................................................................................................... 144
8.2.4.3.1 Market Dynamics ................................................................................................... 144
8.2.4.3.3.1 U.K. Flow Cytometry in Oncology and Immunology Market (by
Application)............................................................................................................ 147
8.2.4.3.3.2 U.K. Flow Cytometry in Oncology and Immunology Market (by Type of
Cancer).................................................................................................................. 147
8.2.4.4 Italy .................................................................................................................. 148
8.2.4.4.1 Market Dynamics ................................................................................................... 148
8.2.4.4.3.1 Italy Flow Cytometry in Oncology and Immunology Market (by
Application)............................................................................................................ 150
8.2.4.4.3.2 Italy Flow Cytometry in Oncology and Immunology Market (by Type of
Cancer).................................................................................................................. 151
8.2.4.5 Spain................................................................................................................ 151
8.2.4.5.1 Market Dynamics ................................................................................................... 151
8.2.4.5.3.1 Spain Flow Cytometry in Oncology and Immunology Market (by
Application)............................................................................................................ 154
8.2.4.5.3.2 Spain Flow Cytometry in Oncology and Immunology Market (by Type of
Cancer).................................................................................................................. 154

9
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
8.2.4.6 Netherlands ..................................................................................................... 155
8.2.4.6.1 Market Dynamics ................................................................................................... 155
8.2.4.6.3.1 Netherlands Flow Cytometry in Oncology and Immunology Market (by
Application)............................................................................................................ 157
8.2.4.6.3.2 Netherlands Flow Cytometry in Oncology and Immunology Market (by
Type of Cancer)..................................................................................................... 157
8.2.4.7 Rest-of-Europe ................................................................................................ 158
8.3 Asia-Pacific Flow Cytometry in Oncology and Immunology Market.........159
8.3.2 Market Dynamics.......................................................................................160
8.3.2.1 Impact Analysis ............................................................................................. 160
8.3.4 Asia-Pacific Flow Cytometry in Oncology and Immunology Market
(by Country) ...............................................................................................162
8.3.4.1 China ............................................................................................................... 162
8.3.4.1.1 Market Dynamics ................................................................................................... 162
8.3.4.1.3.1 China Flow Cytometry in Oncology and Immunology Market (by
Application)............................................................................................................ 165
8.3.4.1.3.2 China Flow Cytometry in Oncology and Immunology Market (by Type of
Cancer).................................................................................................................. 165
8.3.4.2 Japan............................................................................................................... 166
8.3.4.2.1 Market Dynamics ................................................................................................... 166
8.3.4.2.3.1 Japan Flow Cytometry in Oncology and Immunology Market (by
Application)............................................................................................................ 168

10
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
8.3.4.2.3.2 Japan Flow Cytometry in Oncology and Immunology Market (by Type of
Cancer).................................................................................................................. 169
8.3.4.3 India................................................................................................................. 170
8.3.4.3.1 Market Dynamics ................................................................................................... 170
8.3.4.3.3.1 India Flow Cytometry in Oncology and Immunology Market (by
Application)............................................................................................................ 172
8.3.4.3.3.2 India Flow Cytometry in Oncology and Immunology Market (by Type of
Cancer).................................................................................................................. 173
8.3.4.4 Australia........................................................................................................... 174
8.3.4.4.1 Market Dynamics ................................................................................................... 174
8.3.4.4.3.1 Australia Flow Cytometry in Oncology and Immunology Market (by
Application)............................................................................................................ 176
8.3.4.4.3.2 Australia Flow Cytometry in Oncology and Immunology Market (by Type
of Cancer).............................................................................................................. 177
8.3.4.5 South Korea..................................................................................................... 178
8.3.4.5.1 Market Dynamics ................................................................................................... 178
8.3.4.5.3.1 South Korea Flow Cytometry in Oncology and Immunology Market (by
Application)............................................................................................................ 180
8.3.4.5.3.2 South Korea Flow Cytometry in Oncology and Immunology Market (by
Type of Cancer)..................................................................................................... 180
8.3.4.6 Singapore ........................................................................................................ 181
8.3.4.6.1 Market Dynamics ................................................................................................... 181

11
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
8.3.4.6.3.1 Singapore Flow Cytometry in Oncology and Immunology Market (by
Application)............................................................................................................ 183
8.3.4.6.3.2 Singapore Flow Cytometry in Oncology and Immunology Market (by
Type of Cancer)..................................................................................................... 184
8.3.4.7 Rest-of-Asia-Pacific ......................................................................................... 185
8.3.4.7.1 Market Dynamics ................................................................................................... 185
8.4 Latin America Flow Cytometry in Oncology and Immunology Market .....186
8.4.2 Market Dynamics.......................................................................................187
8.4.2.1 Impact Analysis ............................................................................................. 187
8.4.4 Latin America Flow Cytometry in Oncology and Immunology
Market (by Country)...................................................................................188
8.4.4.1 Mexico ............................................................................................................. 189
8.4.4.1.1 Market Dynamics ................................................................................................... 189
8.4.4.1.3.1 Mexico Flow Cytometry in Oncology and Immunology Market (by
Application)............................................................................................................ 191
8.4.4.1.3.2 Mexico Flow Cytometry in Oncology and Immunology Market (by Type
of Cancer).............................................................................................................. 191
8.4.4.2 Brazil................................................................................................................ 192
8.4.4.2.1 Market Dynamics ................................................................................................... 192
8.4.4.2.3.1 Brazil Flow Cytometry in Oncology and Immunology Market (by
Application)............................................................................................................ 194
8.4.4.2.3.2 Brazil Flow Cytometry in Oncology and Immunology Market (by Type of
Cancer).................................................................................................................. 195
8.4.4.3 Rest-of-Latin America...................................................................................... 195

12
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
8.4.4.3.1 Market Dynamics ................................................................................................... 195
8.5 Rest-of-the-World Flow Cytometry in Oncology and Immunology
Market .............................................................................................................197
8.5.2 Market Dynamics.......................................................................................197
8.5.2.1 Impact Analysis ............................................................................................. 197
9. Competitive Benchmarking & Company Profiles ......................199
9.1 Competitive Landscape ................................................................................200
9.1.1 Key Strategies and Developments...........................................................200
9.1.1.1 New Offerings.................................................................................................. 201
9.1.1.2 Mergers and Acquisitions ................................................................................ 202
9.1.1.3 Partnerships, Alliances, and Business Expansions ......................................... 203
9.1.1.4 Regulatory and Legal Activities ....................................................................... 204
9.1.1.5 Funding Activities............................................................................................. 205
9.2 Market Share Analysis ..................................................................................206
9.3 Growth-Share Analysis .................................................................................207
9.3.1 Company....................................................................................................207
9.3.2 Technology ................................................................................................209
9.3.3 Type of Cancer...........................................................................................210
9.3.4 Application.................................................................................................212
9.4 Company Profile ............................................................................................214
9.4.1 Agilent Technologies, Inc.........................................................................214
9.4.1.1 Company Overview ......................................................................................... 214
9.4.1.2 Role of Agilent Technologies, Inc in the Global Flow Cytometry in Oncology
and Immunology Market .................................................................................. 214
9.4.1.3 Financials......................................................................................................... 216
9.4.1.4 Key Customers ................................................................................................ 218
9.4.1.5 Recent Developments ..................................................................................... 218

13
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
9.4.1.6 Analyst Perception........................................................................................... 218
9.4.2 Becton, Dickinson and Company.............................................................219
9.4.2.2 Role of Becton, Dickinson and Company in the Global Flow Cytometry in
Oncology and Immunology Market.................................................................. 219
9.4.2.3 Financials......................................................................................................... 221
9.4.2.4 Key Customers ................................................................................................ 223
9.4.3 Bio-Rad Laboratories, Inc.........................................................................225
9.4.3.2 Role of Bio-Rad Laboratories, Inc. in the Global Flow Cytometry in
9.4.3.3 Financials......................................................................................................... 227
9.4.3.4 Key Customers ................................................................................................ 229
9.4.4 Cell Signaling Technology, Inc.................................................................230
9.4.4.2 Role of Cell Signaling Technology, Inc. in the Global Flow Cytometry in
9.4.4.3 Key Customers ................................................................................................ 232
9.4.5 Cytek Biosciences, Inc..............................................................................233
9.4.5.2 Role of Cytek Biosciences, Inc. in the Global Flow Cytometry in Oncology
9.4.5.3 Financials......................................................................................................... 234
9.4.5.4 Key Customers ................................................................................................ 236
9.4.6 Danaher Corporation.................................................................................237

14
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
9.4.6.2 Role of Danaher Corporation in the Global Flow Cytometry in Oncology
9.4.6.3 Financials......................................................................................................... 239
9.4.6.4 Key Customers ................................................................................................ 241
9.4.7 DiaSorin S.p.A (Luminex Corporation)....................................................242
9.4.7.2 Role of DiaSorin S.p.A in the Global Flow Cytometry in Oncology and
Immunology Market ......................................................................................... 242
9.4.7.3 Financials......................................................................................................... 244
9.4.7.4 Key Customers ................................................................................................ 246
9.4.8 Enzo Biochem Inc......................................................................................248
9.4.8.2 Role of Enzo Biochem Inc. in the Global Flow Cytometry in Oncology and
9.4.8.3 Financials......................................................................................................... 249
9.4.8.4 Key Customers ................................................................................................ 251
9.4.9 Laboratory Corporation of America Holdings ........................................252
9.4.9.2 Role of Laboratory Corporation of America Holdings in the Global Flow
Cytometry in Oncology and Immunology Market............................................. 252
9.4.9.3 Financials......................................................................................................... 253
9.4.9.4 Key Customers ................................................................................................ 255
9.4.10 Merck KGaA ...............................................................................................256

15
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
9.4.10.2 Role of Merck KGaA in the Global Flow Cytometry in Oncology and
9.4.10.3 Financials......................................................................................................... 257
9.4.10.4 Key Customers ................................................................................................ 259
9.4.11 Miltenyi Biotec ...........................................................................................261
9.4.11.2 Role of Miltenyi Biotec in the Global Flow Cytometry in Oncology and
9.4.11.3 Key Customers ................................................................................................ 262
9.4.12 NeoGenomics Laboratories, Inc...............................................................264
9.4.12.2 Role of NeoGenomics Laboratories, Inc. in the Global Flow Cytometry in
9.4.12.3 Financials......................................................................................................... 265
9.4.12.4 Key Customers ................................................................................................ 267
9.4.13 OPKO Health, Inc.......................................................................................268
9.4.13.2 Role of OPKO Health, Inc. in the Global Flow Cytometry in Oncology and
9.4.13.3 Financials......................................................................................................... 269
9.4.13.4 Key Customers ................................................................................................ 271
9.4.14 Sony Group Corporation ..........................................................................273
9.4.14.2 Role of Sony Group Corporation in the Global Flow Cytometry in Oncology

16
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
9.4.14.3 Financials......................................................................................................... 275
9.4.14.4 Key Customers ................................................................................................ 277
9.4.15 Thermo Fisher Scientific Inc ....................................................................278
9.4.15.2 Role of Thermo Fisher Scientific Inc. in the Global Flow Cytometry in
9.4.15.3 Financials......................................................................................................... 280
9.4.15.4 Key Customers ................................................................................................ 282

17
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
List of Figures
Figure 1: Global Flow Cytometry in Oncology and Immunology Market (by End User), $Million, 2021 and
2032
Figure 2: Global Flow Cytometry in Oncology and Immunology Market, Impact Analysis
Figure 3: Global Flow Cytometry in Oncology and Immunology Market (by Region), $Million, 2022 and
2032
Figure 4: Global Flow Cytometry in Oncology and Immunology Market Segmentation
Figure 5: Global Flow Cytometry in Oncology and Immunology Market Research Methodology
Figure 6: Primary Research
Figure 7: Secondary Research
Figure 8: Data Triangulation
Figure 9: Global Flow Cytometry in Oncology and Immunology, Research Process
Figure 10: Assumptions and Limitations
Figure 11: Global Addressable Market Size and Growth Potential ($Million), 2021-2032
Figure 12: Global Addressable Market Size and Growth Potential (by Region), $Million, 2021-2032
Figure 13: Industry Participants Landscape
Figure 14: Increase in Spending on Cancer Care
Figure 15: Cost of Cancer Treatment by Different Groups
Figure 16: Price Sensitivity Analysis
Figure 17: Global Flow Cytometry in Oncology and Immunology Market, Pre-COVID-19, $Million, 2018-
2032
Figure 18: Global Flow Cytometry in Oncology and Immunology Market, Impact Analysis
Figure 19: Cancer Prevalence Forecast (by Region) (2020, 2030, and 2040)
Figure 20: Global Flow Cytometry in Oncology and Immunology Market (by Technology)
Figure 21: Flow Cytometry in Oncology and Immunology Market Opportunity (by Technology), $Million,
2021-2032
Figure 22: Global Flow Cytometry in Oncology and Immunology Market (Cell-Based Flow Cytometry),
$Million, 2020-2032
Figure 23: Global Flow Cytometry in Oncology and Immunology Market (Bead-Based Flow Cytometry),
$Million, 2020-2032
Figure 24: Global Flow Cytometry in Oncology and Immunology Market (by Offering)
Figure 25: Global Flow Cytometry in Oncology and Immunology Market Opportunity (by Offering),
$Million, 2021-2032

18
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
Figure 26: Global Flow Cytometry in Oncology and Immunology Market (Products), $Million, 2020-2032
Figure 27: Global Flow Cytometry in Oncology and Immunology Market (Instruments), $Million, 2020-2032
Figure 28: Global Flow Cytometry in Oncology and Immunology Market (Reagents and Consumables),
$Million, 2020-2032
Figure 29: Global Flow Cytometry in Oncology and Immunology Market (Software), $Million, 2020-2032
Figure 30: Global Flow Cytometry in Oncology and Immunology Market (Services), $Million, 2020-2032
Figure 31: Global Flow Cytometry in Oncology and Immunology Market (by Application)
Figure 32: Global Flow Cytometry in Oncology and Immunology Market Opportunity (by Application),
$Million, 2021-2032
Figure 33: Global Flow Cytometry in Oncology and Immunology Market (Translational Research), $Million,
2020-2032
Figure 34: Global Flow Cytometry in Oncology and Immunology Market (Clinical Research), $Million,
2020-2032
Figure 35: Global Flow Cytometry in Oncology and Immunology Market (Screening and Diagnostics),
$Million, 2020-2032
Figure 36: Global Flow Cytometry in Oncology and Immunology Market (Monitoring and Treatment),
$Million, 2020-2032
Figure 37: Global Flow Cytometry in Oncology and Immunology Market (by Type)
Figure 38: Global Flow Cytometry in Oncology and Immunology Market (by Type), 2021-2032
Figure 39: Global Flow Cytometry in Oncology and Immunology Market (Immunology), $Million, 2020-
2032
Figure 40: Global Flow Cytometry in Oncology and Immunology Market (by Oncology), $Million, 2020-
2032
Figure 41: Global Flow Cytometry in Oncology and Immunology Market (Oncology (by Type of Cancer))
Figure 42: Global Flow Cytometry in Oncology and Immunology Market (Oncology (by Type of Cancer)),
$Million, 2021 and 2032
Figure 43: Global Flow Cytometry in Oncology and Immunology Market (Hematological Malignancies),
$Million, 2020-2032
Figure 44: Global Flow Cytometry in Oncology and Immunology Market (by Hematological Malignancies),
$Million, 2021 and 2032
Figure 45: Global Flow Cytometry in Oncology and Immunology Market, Hematological Malignancies
(Lymphoma), $Million, 2020-2032
(Leukemia), $Million, 2020-2032

19
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
(Myeloma), $Million, 2020-2032
(Other Hematological Malignancies), $Million, 2020-2032
Figure 49: Global Flow Cytometry in Oncology and Immunology Market, Hematological Malignancies (by
Technology), $Million, 2020-2032
Figure 50: Global Flow Cytometry in Oncology and Immunology Market (Solid Tumor) $Million, 2020-2032
Figure 51: Global Flow Cytometry in Oncology and Immunology Market (by Solid Tumor), $Million, 2021
and 2032
Figure 52: Global Flow Cytometry in Oncology and Immunology Market, Solid Tumor (Breast Cancer),
$Million, 2020-2032
Figure 53: Global Flow Cytometry in Oncology and Immunology Market, Solid Tumor (Prostate Cancer),
$Million, 2020-2032
Figure 54: Global Flow Cytometry in Oncology and Immunology Market, Solid Tumor (Colorectal Cancer),
$Million, 2020-2032
Figure 55: Global Flow Cytometry in Oncology and Immunology Market, Solid Tumor (Lung Cancer),
$Million, 2020-2032
Figure 56: Global Flow Cytometry in Oncology and Immunology Market, Solid Tumor (Liver Cancer),
$Million, 2020-2032
Figure 57: Global Flow Cytometry in Oncology and Immunology Market, Solid Tumor (Ovarian Cancer),
$Million, 2020-2032
Figure 58: Global Flow Cytometry in Oncology and Immunology Market, Solid Tumor (Other Solid
Tumors), $Million, 2020-2032
Figure 59: Global Flow Cytometry in Oncology and Immunology Market, Solid Tumor Testing (by
Technology), $Million, 2020-2032
Figure 60: Global Flow Cytometry in Oncology and Immunology Market (by End User)
Figure 61: Flow Cytometry in Oncology and Immunology Market Opportunity (by End User), $Million,
2021-2032
Figure 62: Global Flow Cytometry in Oncology and Immunology Market (Hospitals, Diagnostic
Laboratories, and Reference Laboratories), $Million, 2020-2032
Figure 63: Global Flow Cytometry in Oncology and Immunology Market (Pharmaceutical and
Biotechnology Companies), $Million, 2020-2032
Figure 64: Global Flow Cytometry in Oncology and Immunology Market (Academic Research Institutes),
$Million, 2020-20322032

20
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
Figure 65: Global Flow Cytometry in Oncology and Immunology Market (Contract Research
Organizations), $Million, 2020-2032
Figure 66: Global Flow Cytometry in Oncology and Immunology Market (Others), $Million, 2020-2032
Figure 67: Global Flow Cytometry in Oncology and Immunology Market Share (by Region), 2021-2032
Figure 68: North America Flow Cytometry in Oncology and Immunology Market Incremental Opportunity
(by Country), $Million, 2021-2032
Figure 69: North America Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 70: North America Flow Cytometry in Oncology and Immunology Market (by Country), Share (%),
2022 and 2032
Figure 71: Cancer Incidence (by Type of Cancer, Solid Tumor), 2021 vs. 2032
Figure 72: Cancer Incidence (by Type of Cancer, Hematological Malignancies), 2021 vs. 2032
Figure 73: U.S. Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 74: U.S. Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-
2032
Figure 75: U.S. Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million, 2020-
2032
Figure 78: Canada Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 79: Canada Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-
2032
Figure 80: Canada Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million,
2020-2032
Figure 81: Europe Flow Cytometry in Oncology and Immunology Market Incremental Opportunity (by
Country), $Million, 2021-2032
Figure 82: Europe Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 83: Europe Flow Cytometry in Oncology and Immunology Market (by Country), Share (%), 2021
and 2032
Figure 86: Germany Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 87: Germany Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-
2032

21
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
Figure 88: Germany Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million,
2020-2032
Figure 91: France Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 92: France Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-
2032
Figure 93: France Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million,
2020-2032
Figure 96: U.K. Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 97: U.K. Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-
2032
Figure 98: U.K. Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million, 2020-
2032
Figure 101: Italy Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 102: Italy Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-2032
Figure 103: Italy Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million, 2020-
2032
Figure 106: Spain Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 107: Spain Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-
2032
Figure 108: Spain Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million,
2020-2032
Figure 111: Netherlands Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 112: Netherlands Flow Cytometry in Oncology and Immunology Market (by Application), $Million,
2020-2032

22
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
Figure 113: Netherlands Flow Cytometry in Oncology and Immunology Market (by Type of Cancer),
$Million, 2020-2032
Figure 114: Rest-of-Europe Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 115: Asia-Pacific Flow Cytometry in Oncology and Immunology Market Incremental Opportunity (by
Country), $Million, 2021-2032
Figure 116: Asia-Pacific Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 117: Asia-Pacific Flow Cytometry in Oncology and Immunology Market (by Country), Share (%),
2022 and 2032
Figure 120: China Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 121: China Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-
2032
Figure 122: China Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million,
2020-2032
Figure 125: Japan Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 126: Japan Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-
2032
Figure 127: Japan Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million,
2020-2032
Figure 130: India Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 131: India Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-
2032
Figure 132: India Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million, 2020-
2032
Figure 135: Australia Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 136: Australia Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-
2032

23
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
Figure 137: Australia Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million,
2020-2032
Figure 140: South Korea Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 141: South Korea Flow Cytometry in Oncology and Immunology Market (by Application), $Million,
2020-2032
Figure 142: South Korea Flow Cytometry in Oncology and Immunology Market (by Type of Cancer),
$Million, 2020-2032
Figure 145: Singapore Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 146: Singapore Flow Cytometry in Oncology and Immunology Market (by Application), $Million,
2020-2032
Figure 147: Singapore Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million,
2020-2032
Figure 148: Rest-of-Asia-Pacific Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 149: Latin America Flow Cytometry in Oncology and Immunology Market Incremental Opportunity
(by Country), $Million, 2021-2032
Figure 150: Latin America Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 151: Latin America Flow Cytometry in Oncology and Immunology Market (by Country), Share (%),
2022 and 2032
Figure 154: Mexico Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 155: Mexico Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-
2032
Figure 156: Mexico Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million,
2020-2032
Figure 159: Brazil Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 160: Brazil Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-
2032

24
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
Figure 161: Brazil Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million,
2020-2032
Figure 162: Rest-of-Latin America Flow Cytometry in Oncology and Immunology Market, $Million, 2020-
2032
Figure 163: Rest-of-the-World Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 164: Share of Key Developments and Strategies, January 2018-October 2022
Figure 165: New Offerings (by Company), January 2018-October 2022
Figure 166: Mergers and Acquisitions (by Company), January 2018-October 2022
Figure 167: Partnerships, Alliances, and Business Expansions (by Company), January 2018-October 2022
Figure 168: Regulatory and Legal Activities (by Company), January 2018-October 2022
Figure 169: Funding Activities (by Company), January 2018-October 2022
Figure 170: Global Flow Cytometry in Oncology and Immunology Market, Company Revenue Share
Analysis, $Million, 2021
Figure 171: Growth-Share Analysis for Global Flow Cytometry in Oncology and Immunology Market (by
Company), 2021
Technology), 2021-2032
Type of Cancer), 2021-2032
Application), 2021-2032
Figure 175: Agilent Technologies, Inc: Product Portfolio
Figure 176: Agilent Technologies, Inc: Overall Financials, $Million, 2019-2021
Figure 177: Agilent Technologies, Inc: Segment Revenues, $Million, 2019-2021
Figure 178: Agilent Technologies, Inc: Net Revenue (by Region), $Million, 2019-2021
Figure 179: Agilent Technologies, Inc: R&D Expenditure, $Million, 2019-2021
Figure 180: Becton, Dickinson and Company: Product Portfolio
Figure 181: Becton, Dickinson and Company: Overall Financials, $Million, 2019-2021
Figure 182: Becton, Dickinson and Company: Segment Revenues, $Million, 2019-2021
Figure 183: Becton, Dickinson and Company: Net Revenue (by Region), $Million, 2019-2021
Figure 184: Becton, Dickinson and Company: R&D Expenditure, $Million, 2019-2021
Figure 185: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 186: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
Figure 187: Bio-Rad Laboratories, Inc.: Segment Revenues, $Million, 2019-2021

25
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
Figure 188: Bio-Rad Laboratories, Inc.: Net Revenue (by Region), $Million, 2019-2021
Figure 189: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 190: Cell Signaling Technology, Inc.: Product Portfolio
Figure 191: Cytek Biosciences, Inc.: Product Portfolio
Figure 192: Cytek Biosciences, Inc.: Overall Financials, $Million, 2020-2021
Figure 193: Cytek Biosciences, Inc.: Net Revenue (by Region), $Million, 2020-2021
Figure 194: Cytek Biosciences, Inc.: R&D Expenditure, $Million, 2020-2021
Figure 195: Danaher Corporation: Product Portfolio
Figure 196: Danaher Corporation: Overall Financials, $Million, 2019-2021
Figure 197: Danaher Corporation: Segment Revenues, $Million, 2019-2021
Figure 198: Danaher Corporation: Net Revenue (by Region), $Million, 2019-2021
Figure 199: Danaher Corporation: R&D Expenditure, $Million, 2019-2021
Figure 200: DiaSorin S.p.A: Product Portfolio
Figure 201: DiaSorin S.p.A: Overall Financials, $Million, 2019-2021
Figure 202: DiaSorin S.p.A: Segment Revenues, $Million, 2019-2021
Figure 203: DiaSorin S.p.A: Net Revenue (by Region), $Million, 2019-2021
Figure 204: DiaSorin S.p.A: R&D Expenditure, $Million, 2019-2021
Figure 205: Enzo Biochem Inc.: Product Portfolio
Figure 206: Enzo Biochem Inc.: Overall Financials, $Million, 2020-2022
Figure 207: Enzo Biochem Inc.: Segment Revenues, $Million, 2020-2022
Figure 208: Enzo Biochem Inc.: Net Revenue (by Region), $Million, 2020-2022
Figure 209: Enzo Biochem Inc.: R&D Expenditure, $Million, 2020-2022
Figure 210: Laboratory Corporation of America Holdings: Product Portfolio
Figure 211: Laboratory Corporation of America Holdings: Overall Financials, $Million, 2019-2021
Figure 212: Laboratory Corporation of America Holdings: Segment Revenues, $Million, 2019-2021
Figure 213: Laboratory Corporation of America Holdings: Net Revenue (by Region), $Million, 2020-2021
Figure 214: Merck KGaA: Product Portfolio
Figure 215: Merck KGaA: Overall Financials, $Million, 2019-2021
Figure 216: Merck KGaA: Segment Revenues, $Million, 2020-2021
Figure 217: Merck KGaA: Net Revenue (by Region), $Million, 2019-2021
Figure 218: Merck KGaA: R&D Expenditure, $Million, 2019-2021
Figure 219: Miltenyi Biotec: Product Portfolio
Figure 220: NeoGenomics Laboratories, Inc.: Product Portfolio

26
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
Figure 221: NeoGenomics Laboratories, Inc.: Overall Financials, $Million, 2019-2021
Figure 222: NeoGenomics Laboratories, Inc.: Segment Revenues, $Million, 2019-2021
Figure 223: NeoGenomics Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 224: OPKO Health, Inc.: Product Portfolio
Figure 225: OPKO Health, Inc.: Overall Financials, $Million, 2019-2021
Figure 226: OPKO Health, Inc.: Segment Revenues, $Million, 2019-2021
Figure 227: OPKO Health, Inc.: Net Revenue (by Region), $Million, 2019-2021
Figure 228: OPKO Health, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 229: Sony Group Corporation: Product Portfolio
Figure 230: Sony Group Corporation: Overall Financials, $Million, 2019-2021
Figure 231: Sony Group Corporation: Segment Revenues, $Million, 2019-2021
Figure 232: Sony Group Corporation: Net Revenue (by Region), $Million, 2019-2021
Figure 233: Sony Group Corporation: R&D Expenditure, $Million, 2019-2021
Figure 234: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 235: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
Figure 236: Thermo Fisher Scientific Inc.: Segment Revenues, $Million, 2019-2021
Figure 237: Thermo Fisher Scientific Inc.: Net Revenue (by Region), $Million, 2019-2021
Figure 238: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021

27
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
List of Tables
Table 1: Key Challenges and Possible Solutions for Stakeholders in the Global Flow Cytometry in
Oncology and Immunology Market
Table 2: Global Flow Cytometry in Oncology and Immunology Market, Key Developments Analysis,
January 2018-October 2022
Table 3: Key Questions Answered in the Report
Table 4: Presence of Key Healthcare Infrastructure Across the Asia-Pacific Region
Table 5: Global Flow Cytometry in Oncology and Immunology Market, Product Mapping Analysis (by
Offering)
Table 6: Global Flow Cytometry in Oncology and Immunology Market, Product Mapping Analysis (by
Product)
Table 7: North America Flow Cytometry in Oncology and Immunology Market, Impact Analysis
Table 8: Europe Flow Cytometry in Oncology and Immunology Market, Impact Analysis
Table 9: Asia-Pacific Flow Cytometry in Oncology and Immunology Market, Impact Analysis
Table 10: Latin America Flow Cytometry in Oncology and Immunology Market, Impact Analysis
Table 11: Rest-of-the-World Flow Cytometry in Oncology and Immunology Market, Impact Analysis

28
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
BIS Research Offerings:
We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s
digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions
worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other
innovative solutions.
Know More Know More
Know More
Know More

29
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
Disclaimer
BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to
orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth.
This document and its contents are confidential and may not be further distributed, published or reproduced,
in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS
Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly
through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information
to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce
Information in legal proceedings.
Market reports are based on expectations, estimates and projections as of the date such information is
available. Any recommendation contained in this report may not be suitable for all investors or businesses.
The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to
market fluctuations and business, economic and competitive uncertainties and contingencies.
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135

30
G
l
o
b
a
l
F
l
o
w
C
y
t
o
m
e
t
r
y
i
n
O
n
c
o
l
o
g
y
a
n
d
I
m
m
u
n
o
l
o
g
y
M
a
r
k
e
t
BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544
www.bisresearch.com

Flow Cytometry in Oncology and Immunology Market Analysis and Forecast, 2022-2032

Recommended

Recommended

More Related Content

Similar to Flow Cytometry in Oncology and Immunology Market Analysis and Forecast, 2022-2032

Similar to Flow Cytometry in Oncology and Immunology Market Analysis and Forecast, 2022-2032 (20)

More from BIS Research Inc.

More from BIS Research Inc. (20)

Recently uploaded

Recently uploaded (20)

Flow Cytometry in Oncology and Immunology Market Analysis and Forecast, 2022-2032